BioSpace News Archive

Salubris Biotherapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, announced positive updated results from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction.

Senti Biosciences, Inc. announced multiple presentations highlighting the broad application of its Gene Circuit technologies in multiple modalities at the American Society of Gene and Cell Therapy annual meeting in Los Angeles, CA.

Abbott announced late-breaking results from the AVEIR™ dual-chamber i2i™ Investigational Device Exemption study, a large-scale study to assess the world’s first dual-chamber leadless pacemaker, showing that the leadless pacemaker met its three prespecified primary endpoints for safety and performance.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that four studies across its neuroscience portfolio will be presented during the American Psychiatric Association’s 2023 Annual Meeting taking place on May 20-24, 2023.

Boston Scientific Corporation announced data supporting use of the company’s key electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX™ Left Atrial Appendage Closure Device.

Neurimmune announced that primary results of its Phase 1 proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR cardiomyopathy, have been presented in Prague at Heart Failure 2023, a scientific congress of the European Society of Cardiology, and published in The New England Journal of Medicine.

Cytokinetics, Incorporated announced that additional data from Cohort 4 of REDWOOD-HCM, a Phase 2, open-label clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy, were presented in a Late Breaking Clinical Trial session at Heart Failure 2023 an International Congress of the European Society of Cardiology taking place online and in Prague, Czech Republic from May 20, 2023 – May 23, 2023.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced new results from an interim analysis of exploratory data from the open-label extension period of the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy.

Medtronic plc, a global leader in healthcare technology, announced longer-term follow-up results of its investigational EV ICD™ System, designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest.